Presentation Goals 4/14/2015. Pharmacology for Urinary Incontinence in Women. Medications Review anti muscarinic medications Focus on newer meds

Similar documents
Urinary Incontinence for the Primary Care Provider

Overactive bladder (OAB) affects approximately 15% of the adult population. Diagnosis is based

Overactive Bladder (OAB) Step Therapy Program Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:

Overactive Bladder (OAB) Step Therapy Program

Is There a Best Drug for Overactive Bladder in a Patient with Dementia?

Evaluation & Management of Overactive Bladder

THE OVER-ACTIVE BLADDER (OAB)

The Management of Overactive Bladder Syndrome with Antimuscarinic Drugs

Geriatric Urinary Incontinence

Primary Care management of Overactive Bladder (OAB)

URGE MOTOR INCONTINENCE

Drugs for Overactive Bladder (OAB)

Overactive Bladder. Jennifer Mosher, WHNP-BC, CUNP Mercy Health Pelvic Medicine and Urogynecology Muskegon, Michigan

Dr. Melissa Kagarise, PA C

Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.

Urinary Incontinence. Lee A. Jennings, MD, MSHS. Assistant Professor Reynolds Department of Geriatrics University of Oklahoma Health Sciences Center

Management of OAB. Lynsey McHugh. Consultant Urological Surgeon. Lancashire Teaching Hospitals

CDEC FINAL RECOMMENDATION

Overactive Bladder. When to see a doctor. Normal bladder function

Evaluation and Treatment of Incontinence

Report on New Patented Drugs - Vesicare

Supplement. Updated Literature Search for Pharmacologic Treatments for Urgency UI

Rational Pharmacotherapy for LUTS in Older People. Dr William Gibson MBChB MRCP

CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION

TREATMENT OF OVERACTIVE BLADDER IN ADULTS FUGA 2016 KGH

Urinary Incontinence. Alison A Moore, MD, FACP

Taking Control of your Bladder, or. Don't make me laugh when laughter isn't the best medicine: a discussion on urinary incontinence

Managing urinary incontinence in the elderly

Overactive Bladder Syndrome

Innovations in Childhood Incontinence: Neurogenic and Functional Bladder Disorders

Urinary Incontinence: The Neglected Geriatric Syndrome. Dr. Martha Spencer, MD, FRCPC Providence Health Care Clinical Instructor, UBC

Objectives. Prevalence of Urinary Incontinence URINARY INCONTINENCE: EVALUATION AND CURRENT TREATMENT OPTIONS

Urinary Incontinence. Vibhash Mishra Consultant Urological Surgeon Royal Free Hospital

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine

Overactive Bladder: Identifying Patients at Risk, Implementing New Strategies

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline.

Neuromuscular Blocking Agents

Drug Class Review Agents for Overactive Bladder

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

RECENT ADVANCES IN THE MANAGEMENT OF URINARY INCONTINENCE

SELECTED POSTER PRESENTATIONS

Urogynecology Office. Can You Hold? An Update on the Treatment of OAB. Can You Hold? Urogynecology Office

Appendix 2 Drug Information

Dee E. Fenner, M.D. Chair and Furlong Professor of Women s Health Dept. of Obstetrics and Gynecology University of Michigan.

ril 2014 FINAL CONSOLIDATED REPORT MARCH 2016 Treatment of Overactive Bladder

Bladder dysfunction in ALD and AMN

Urinary Incontinence in Women: Never an Acceptable Consequence of Aging

URINARY INCONTINENCE

North Georgia Urology Center, P.C. Urology Patient Questionnaire

R. Matthew Smith M.D. Mercy Urology

Etiology, risk factors, and management overactive bladder : Review

FDA Briefing Document for Nonprescription Drugs Advisory Committee

Some people experience occasional, minor leaks of urine. Others wet their clothes frequently.

Report on New Patented Drugs Enablex

Disclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.

The International Urogynecological Association and the

Dr Jonathan Evans Paediatric Nephrologist

I. Uniform Formulary Review Process

Uniform Formulary Beneficiary Advisory Panel Handout February 2006

OVERACTIVE BLADDER (OAB)

Urodynamic Studies. An information guide

Pharmacologic management of overactive bladder

NEW DEVELOPMENTS IN HYPERTENSION. Clinical Issues in Geriatrics for Primary Care Practice

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

OAB Treatment Guidelines

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

The Ontario Drug Policy Research Network Drug Class Review on Medications for Overactive Bladder (OAB)

Female Urinary Incontinence

STRATEGIES TO ADDRESS URINARY INCONTINENCE EVERY PHYSICAL THERAPIST SHOULD KNOW

R. Matthew Smith M.D. Stacy Pohlman, ARNP Jessica Gengler, PT, DPT Mercy Urology

Overactive bladder. Information for patients from Urogynaecology

Overactive Bladder beyond antimuscarinics

The Effects of AntimuscarinicTreatments in Overactive Bladder: A Systematic Review and Meta-Analysis

NEW DEVELOPMENTS IN HYPERTENSION

The International Continence Society

Common Urology. RMH Grand Rounds Feb Greg Harrington h9p://rmurology.com/

URGENCY INCONTINENCE FLAME LECTURE: 175 BURNS / TABIT

These drugs produce effects similar to the sympathetic nervous system

Urinary incontinence in women & men

STEP THERAPY IN MEDICARE PART D

Pelvic Floor Disorders and the Geriatric Patient

Urinary incontinence (UI) affects many women in the

Prior Authorization Update: Botulinum Toxins

Mifegymiso. New Exception Status Benefits

Safety and Tolerability Profiles of Anticholinergic Agents Used for the Treatment of Overactive Bladder

SenioRx Care Perspective

DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

Latest Press Release. sbn network jimmy swaggart comcast

Possible Effect of Carbamazepine A Sodium Channel Blocker on Urinary Bladder Dysfunction in Type-1 Diabetic Patients

Overactive Bladder Syndrome

Faculty. Louis Kuritzky, MD Clinical Assistant Professor Department of Community Health & Family Medicine University of Florida Gainesville, FL

Study No. 178-CL-008 Report Final Version, 14 Dec 2006 Reissued Version, 18 Jul 2011 Astellas Pharma Europe B.V. Page 13 of 122

OVERACTIVE BLADDER IN THE ELDERLY PATIENT

Efficacy and Adverse Effects of Solifenacin in the Treatment of Lower Urinary Tract Symptoms in Patients With Overactive Bladder

Drugs for the overactive bladder: are there differences in persistence and compliance?

Diagnosis and treatment of overactive bladder (nonneurogenic) in adults: AUA/SUFU guideline.

Botulinum Toxins. Length of Authorization: From 90 days to 12 months

Urinary Incontinence and Overactive Bladder Update NICE Guidelines on UI for women - GP Perspectives

Advanced Care for Female Overactive Bladder & Urinary Incontinence. Department of Urology Kaiser Permanente Santa Rosa

Urogynecology in EDS. Joan L. Blomquist, MD Greater Baltimore Medical Center August 2018

Transcription:

Presentation Goals Pharmacology for Urinary Incontinence in Women Medications Review anti muscarinic medications Focus on newer meds Introduce beta adrenergic medications Current Concepts in Drug Therapy University of Washington Leah Gordon, MD MPH 4/24/15 Question 1 A 60 year old woman with urge incontinence has pursued behavioral modification and pelvic floor training but continues to be bothered by frequent episodes of incontinence and is interested in pharmacologic treatment. She has no other medical problems. She has heard these medications can be expensive and is worried about the potential cost. a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily Question 1 1

Answer 1 Which medication would be appropriate to start for her? a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily S P E C I F I C I T Y OXYBUTYNIN = Ditropan FESOTERODINE = Toviaz TOLTERODINE = Detrol SOLIFENACIN = Vesicare DARIFENACIN = Enablex TROSPIUM = Sanctura M 3 Primary Outcomes in Most Studies: Complete Continence = NO incontinent episodes Clinically Important Improvement = reduction in frequency of incontinent episodes by at least 50% Quality of Life All Anti Muscarinics: Many large, well done RCTs BEST effects reduced incontinence or have clinically important improvement in 20% of women. NO big differences in efficacy across meds 2

Answer 1 An Approach Start Cheap Side Effects? Specific Cases Which medication would be appropriate to start for her? a. Oxybutynin (Ditropan XL) 30mg po daily b. Fesoterodine (Toviaz) 4mg po daily d. Mirabegron (Myrbetriq) 25mg po daily Question 2 Question 2 A 55 year old woman with urge incontinence as well as atrial fibrillation, depression, and diabetes on Metformin, Fluoxetine, and Metoprolol is interested in starting a medication for her incontinence. a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily 3

Answer 2 a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily Start Cheap Side Effects? Specific Cases Answer 2 Start Cheap Side Effects? Interactions a. Darifenacin (Enablex) 7.5mg po daily b. Trospium (Sanctura) 20 mg po daily Trospium 4

Question 3 A 65 year old woman with mixed stress/urge incontinence and no other co morbidities was previously on Trospium without improvement. She is now interested in trying a different medication. switch to for her? a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Question 3 Answer 3 a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Start Cheap Side Effects? Prior treatment? Solifenacin 5

Answer 3 a. Oxybutynin (Ditropan) 5mg po daily b. Trospium (Sanctura) 60mg po daily c. Darifenacin (Enablex) 7.5mg po daily Question 4 A 60 year old woman with early Alzheimer s disease on Donepezil is very bothered by urge incontinence and wants to start a medication. a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily Question 4 Answer 4 a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily 6

Beta adrenergics Caution in: Cognitive Impairment Start Cheap Cholinesterase Inhibitors Side Effects? Combination with other strong anti cholinergics Specific Cases Severe Hepatic Failure Dialysis Beta 3 agonists Mirabegron Solabegron Beta adrenergics Beta adrenergics Beta 3 agonists Beta 3 agonists Mirabegron Mirabegron Solabegron Not yet approved in US Mechanism of Action Beta 3 agonsim Relaxes detrusor muscle Data Similar to About 20% response Side Effects Increase in BP Headache Dizziness Tachycardia GI upset NO: dry mouth, blurry vision 7

Answer 4 Caution in: Cognitive Impairment Start Cheap Cholinesterase Inhibitors Side Effects? Combination with other strong anti cholinergics Specific Cases Severe Hepatic Failure Dialysis Mirabegron? a. Mirabegron (Myrbetriq) 25mg po daily b. Solabegron mg po daily c. Oxybutynin (Ditropan) 5mg po daily d. Trospium (Sanctura) 60mg po daily References Ellsworth PI. The Pharmacologic Management of Idiopathic Overactive Bladder in Primary Care. J Fam Pract 2014;63:S38. Goode PS. Incontinence in Older Women. JAMA 2010;303:2172. Hoffman BL. Williams Gynecology, 2e. The McGraw Hill Companies, Inc. 2012. Imran M. Mirabegron for overactive bladder: a novel, first in class B3 agonist therapy. Urol J 2013 Sep 26;10(3):935 40. Marinkovic SP. The management of overactive bladder syndrome. BMJ 2012;344:32356. Nygaard I. Idiopathic Urgency Urinary Incontinence. N Engl J Med 2010; 363:1156. Nishizawa O. Guidelines for management of urinary incontinence. Int J Uro 2008;15:857. Qaseem A. Nonsurgical management of urinary incontinence in women: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2014;161:429 440. Shamliyan T. Systematic Review: Randomized, Controlled Trials of Nonsurgical Treatments for Urinary Incontinence in Women. Ann Intern Med 2008;148:459. Shamliyan T. Benefits and Harms of Pharmacologic Treatment for Urinary Incontinence in Women. Ann Intern Med 2012;156:861. Wu J. Prevalence and Trends of Symptomatic Pelvic Floor Disorders in US women. Obstet Gyncol 2014;123:141. 8